TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19907103
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg/day for 12 months
Study: 19907103
Drug: Amlodipine besilate
Normalized name: Amlodipine besilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine besilate 5 mg/day for 12 months
Study: 9062436
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of questionnaires
Study: 8383388
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (25 units, intramuscular)
Study: 22199189
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pill (OCP)
Study: 30770758
Drug: L-theanine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine supplementation (150 mg for 6 weeks)
Study: 12904193
Drug: Clonidine 10-min
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 10-min group (3 microg x kg‐1 of clonidine administered for 10 min immediately after the spinal block)
Study: 12904193
Drug: Clonidine 60-min
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 60-min group (3 microg x kg‐1 of clonidine administered for 10 min, 50 min after the spinal block)
Study: 7854171
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 to 40 mg/d)
Study: 1791391
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus 600 mg per day for 30 days
Study: 1791391
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus 1,200 mg per day for 30 days
Study: 26407698
Drug: 38 %
Normalized name: dextrose 38 % in water
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 % silver diamine fluoride (SDF) solution
Study: 19486469
Drug: Peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2a (40 KDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Study: 12969097
Drug: Ephedrine (E)
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine (E) 70 micro g kg‐1
Study: 12969097
Drug: Esmolol (Es)
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol (Es) 500 micro g kg‐1
Study: 6379789
Drug: Fenoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (200 μg) administered by pressurized aerosol
Study: 6379789
Drug: Fenoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (200 μg) administered in powder form
Study: 6379789
Drug: Overall evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall evaluation of both formulations
Study: 11515717
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablet of aqueous extract of Uncaria tomentosa (C‐Med‐100)
Study: 11515717
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg tablet of aqueous extract of Uncaria tomentosa (C‐Med‐100)
Study: 3421258
Drug: Preterm labor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preterm labor education, daily telephone contact, and the Term Guard ambulatory uterine activity monitor (group EM)
Study: 25510746
Drug: SES with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SES with LDL cholesterol < 70 mg/dL
Study: 23186613
Drug: High-dose-rate intraluminal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate intraluminal brachytherapy (ILBT) through percutaneous transhepatic biliary drainage (PTBD)
Study: 19044214
Drug: Venlafaxine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine IR 150 mg
Study: 17699248
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (1 g total, divided into 300 mg over 1.5 h on days 1 and 15, and 400 mg over 2.5 h on day 29)
Study: 8764308
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (SPE) - 52 g of fat replaced, 3.1 MJ, 740 kcal
Study: 1865045
Drug: Methylphenidate (35.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (35.33 mg/day)
Study: 6345421
Drug: Triiodothyronine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine supplementation (50 micrograms, 3 times daily)
Study: 28409566
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of yohimbine (α2-adrenergic antagonist) and hydrocortisone
Study: 27336209
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Letrozole and Berberine
Study: 20865875
Drug: Automated intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated intermittent bolus (2.5 ml every 15 minutes)
Study: 20865875
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (10 ml/hour)
Study: 18441457
Drug: Amlodipine dose‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine dose‐up group
Study: 1683340
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clozapin (reference substance)
Study: 6114503
Drug: therapy responders
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy responders
Study: 6114503
Drug: therapy non-responders
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy non-responders
Study: 31859791
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem 5 mg
Study: 31859791
Drug: Oral zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zolpidem 10 mg
Study: 29578880
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg + Mirabegron 50 mg (combination 5+50 mg)
Study: 29578880
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg + Mirabegron 25 mg (combination 5+25 mg)
Study: 23769122
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg
Study: 23925451
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels ≥ 0.71 μg/mL on admission
Study: 23925451
Drug: D-dimer levels
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer levels ≥ 1.26 μg/mL at discharge
Study: 16199243
Drug: RBX 64
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RBX 64 mg/d
Study: 23404115
Drug: RBX 32
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RBX 32 mg/d
Study: 10500005
Drug: Baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10 mg three times daily for 14 days)
Study: 8961085
Drug: Ephedrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (50 mg, two doses with a 4‐h interval)
Study: 8961085
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg b.i.d.)
Study: 2012398
Drug: Induced hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hypertension chemotherapy (IHC) using angiotensin II human in 8 patients.
Study: 2012398
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy in 5 patients (5‐fluorouracil, adriamycin, mitomycin C).
Study: 19909588
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.2 mg of triptorelin)
Study: 17213972
Drug: Anticholinergic agent
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agent (tolterodine)
Study: 9396886
Drug: Maternal antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibiotics before delivery
Study: 3300348
Drug: 10 units
Normalized name: Omnipod GO 10 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units of oxytocin diluted in physiologic saline solution (20 ml total volume)
Study: 3300348
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of saline solution alone (control)
Study: 29270641
Drug: Heroin (low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (low, medium, high doses)
Study: 29270641
Drug: Hydromorphone (low,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (low, medium, high doses)
Study: 21802161
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/d) and Placebo
Study: 17323733
Drug: Implant-supported mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported mandibular overdentures (ISMOs) delivered after 1 week
Study: 10900712
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (0.92‐1.38 micrograms/kg/min)
Study: 8983567
Drug: 12-h theophylline
Normalized name: 12 HR theophylline 350 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h theophylline (treatment A)
Study: 8983567
Drug: 24-h theophylline
Normalized name: 24 HR theophylline 150 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h theophylline (treatment B)
Study: 8258465
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline 300 mg + salbutamol 4 mg (Drug I)
Study: 8258465
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg + theophylline 300 mg (Drug II)
Study: 8258465
Drug: Salbutamol sustained
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol sustained released (asthalin SA) 8 mg (Drug III)
Study: 8258465
Drug: Salbutamol sustained
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol sustained released (ventorlin CR) 8 mg (Drug IV)
Study: 24551257
Drug: High-frequency electrocauterization
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency electrocauterization (EC) followed by daily moist-wound-treatment (MWT) with DAC N-055 (group I)
Study: 24551257
Drug: High-frequency electrocauterization
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency electrocauterization (EC) followed by daily moist-wound-treatment (MWT) without DAC N-055 (group II)
Study: 7079142
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine
Study: 22070527
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine
Study: 8340055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ribavirin and interferon-beta
Study: 3089939
Drug: LAF +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAF + PSA (laminar air flow isolation plus prophylactic systemic antibiotics)
Study: 23020923
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC
Study: 29300962
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg THC
Study: 29300962
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg THC
Study: 29300962
Drug: 50 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ng/mL cutoff
Study: 29300962
Drug: 20 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ng/mL cutoff
Study: 26475403
Drug: 100 ng/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ng/mL cutoff
Study: 23259002
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil inhalation (lavender, ylang‐ylang, marjoram, neroli blended in a ratio of 20:15:10:2)
Study: 23259002
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil inhalation
Study: 18183613
Drug: HP eradication
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP eradication therapy (amoxicillin, clarithromycin, and omeprazole) for 2 weeks
Study: 18183613
Drug: HP eradication
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP eradication therapy
Study: 12944595
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg or 40 mg of hyoscine butylbromide
Study: 12944595
Drug: rectal balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: rectal balloon catheter
Study: 10102972
Drug: Mesalazine 2
Normalized name: mesalazine 2 GM per 59 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 2 g gel enema
Study: 10102972
Drug: Mesalazine 2
Normalized name: mesalazine 2 GM per 59 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 2 g foam enema
Study: 31387756
Drug: HIPEC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (cisplatin 50 mg/m2 + doxorubicin 50 mg/m2, 42°C, 1 h) combined with radical surgery
Study: 18588449
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with cisplatin/5-fluorouracil (PF)
Study: 10902462
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment strategies (TACE and PEI or RFTA)
Study: 3799443
Drug: Indecainide, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indecainide, 1 mg/kg intravenously
Study: 3799443
Drug: Procainamide, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide, 1000 mg intravenously
Study: 21968670
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment applied weekly for six months
Study: 18617377
Drug: 1.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/day SINETROL
Study: 12729523
Drug: Standard enteral
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard enteral formula (3 cans/day, 250 ml per can)
Study: 10671303
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg GM‐CSF/kg b.w. daily for 6 weeks
Study: 10671303
Drug: GM‐CSF/IFNalpha2b combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF/IFNalpha2b combination
Study: 10671303
Drug: IFNalpha2b monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha2b monotherapy
Study: 10671303
Drug: GM‐CSF therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF therapy
Study: 1739366
Drug: Mupirocin calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin calcium ointment applied to the anterior part of the nares for 5 days
Study: 21817954
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine coadministered with Tdap and/or MCV4
Study: 21817954
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine alone
Study: 21817954
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine coadministered with Tdap
Study: 21817954
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine coadministered with MCV4
Study: 15364708
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 1200 mg/d plus vitamin A
Study: 15364708
Drug: Control capsules
Normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control capsules plus vitamin A
Study: 11046101
Drug: Tasosartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasosartan (100 mg p.o.)
Study: 11046101
Drug: Tasosartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasosartan (50 mg i.v.)
Study: 11046101
Drug: Enoltasosartan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoltasosartan (2.5 mg i.v.)
Study: 9333103
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/day for 8 days)
Study: 8467987
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and diet group (INS)
Study: 3532592
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg cimetidine (400 mg q.i.d.) daily
Study: 3532592
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cimetidine (400 mg b.i.d.) daily
Study: 30124952
Drug: Glucocorticoid combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid combined with MMF therapy (1-1.5 g/day)
Study: 30124952
Drug: Glucocorticoid monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid monotherapy (0.6-0.8 mg/(kg·day) and tapered gradually)
Study: 28858120
Drug: Extracorporeal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal shock-wave therapy (ESWT)
Study: 21614906
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + acetaminophen + ketoprofen
Study: 21614906
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + metamizol + ketoprofen
Study: 22781640
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine therapy only)
Study: 27917806
Drug: Plain articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain articaine 40 mg mixed with fentanyl 20 µg
Study: 27917806
Drug: Plain levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain levobupivacaine 10 mg mixed with fentanyl 20 µg
Study: 24911576
Drug: morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 50 mg + ethanol 0.7 g/kg
Study: 24911576
Drug: morphine 50
Normalized name: MORPHINE 50MG/NALTREXONE 2MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 50 mg + ethanol placebo
Study: 24911576
Drug: morphine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine placebo + ethanol 0.7 g/kg
Study: 24911576
Drug: morphine 30
Normalized name: ethylmorphine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 30 mg or 80 mg (alone and in combination with ethanol)
Study: 24911576
Drug: morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine and ethanol (combined)
Study: 19887878
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg (0.1 ml) bevacizumab
Study: 19887878
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml balanced salt solution
Study: 10675071
Drug: ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (10 mg/day)
Study: 9410237
Drug: Flurbiprofen ED
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen ED twice a day from the first preoperative day to the third postoperative day
Study: 9410237
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears twice a day from the first preoperative day to the third postoperative day
Study: 31896832
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% spray for 8 weeks
Study: 31896832
Drug: Placebo (alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (alcohol spray) for 8 weeks
Study: 25051779
Drug: Reamberin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin in pathogenetic therapy
Study: 22289227
Drug: 120-minute therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-minute therapy sessions involving RTP incorporating the ESN
Study: 22289227
Drug: 60-minute therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute therapy sessions involving RTP incorporating the ESN
Study: 22289227
Drug: 30-minute therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute therapy sessions involving RTP incorporating the ESN
Study: 20462826
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of BSE/CBE, marital status, educational status, knowledge of treatment of breast cancer
Study: 18338963
Drug: Minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal contact physical activity intervention (one group meeting, self-help booklet, five monthly reminder letters)
Study: 12698399
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of pump blood flow from 2.4 to 2.0 L/min/m(2) during hypothermia
Study: 2227074
Drug: Controlled-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release theophylline
Study: 6875530
Drug: Traditional Veterans
Normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Veterans Administration rehabilitation program
Study: 23773886
Drug: Oral second-generation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral second-generation antipsychotics (SGAs)
Study: 17161887
Drug: Glutamine-enriched polymeric
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched polymeric diet (Group G, n=7)
Study: 15047035
Drug: Carvedilol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (20 mg)